KORU Medical Systems, Inc. (KRMD)

NASDAQ: KRMD · USD

$3.19

+0.02 (+0.6%)· Recorded snapshot

Market cap	147.3M
Revenue (ttm)	45.1M
Net income (ttm)	-1.8M
EPS (ttm)	-$0.04
Shares out	46.2M
P/E (forward)	319.0x
Volume	60,077
Beta	0.39

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 45.1M
Net income (ttm): -1.8M
EPS (ttm): -$0.04
P/E (forward): 319.0x
Market cap: 147.3M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	احتفاظ

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E319

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-10.5

P25 n/aP50 n/aP75 n/a

ROIC-13.4

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All KRMD indicators

Market & fundamental data

Available fields

229

Groups with data

Currency

USD

Showing 229 of 229 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0000704440
Company name	KORU Medical Systems, Inc.
Country	United States
Country code	US
CUSIP number	759910102
Earnings date	2026-11-10
Earnings time	amc
Employees	73
Employees change	-7
Employees growth	-8.75%
Enterprise value	$142.3M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1980
In index	RUSSELL2000
Industry	Medical Instruments & Supplies
Is primary listing	Yes
Is SPAC	No
ISIN number	US7599101026
Last 10-K release date	2026-03-12
Last earnings date	2026-08-05
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$147.3M
Market cap category	Micro-Cap
Next earnings date	2026-11-10
Options	Yes
Price	$3.19
Price currency	USD
Sector	Healthcare
SIC code	3841
Stock price date	2026-10-28
Symbol	KRMD
U.S. state	New Jersey
Website	https://www.korumedical.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	106.33x
Earnings yield	-1.25%
EV/FCF	182.64x
EV/Sales	3.14x
FCF / EV yield	0.55%
FCF yield	0.53%
Forward EV/Sales	2.72x
Forward P/E	319x
Forward P/S	2.81x
Industry forward P/E	22.65x
Industry P/E	75.03x
P/B ratio	8.1x
P/FCF ratio	189.05x
P/OCF ratio	105.56x
P/S ratio	3.26x
Price / tangible book value	8.96x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	-3.66%
EBITDA margin	-2.17%
FCF margin	1.72%
Gross margin	62.43%
Operating margin	-3.66%
Pretax margin	-4.01%
Profit margin	-4.03%
Profit per employee	$-24,924
Profitable quarters	1
Revenue per employee	$617,911
ROA	-3.86%
ROA (5Y)	-13.25%
ROCE	-7.95%
ROE	-10.52%
ROE (5Y)	-27.9%
ROIC	-13.44%
ROIC (5Y)	-56.05%
SBC / revenue	6.07%
Tax / revenue	0.02%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	2
Gross profit growth	21.01%
Gross profit growth (Q)	21.16%
Gross profit growth 3Y	19.66%
Gross profit growth 5Y	17.3%
Net income growth quarters	7
Net income growth years	2
OCF growth (QoQ)	1,373.87%
OCF growth 10Y	0.32%
Revenue growth	22.41%
Revenue growth (Q)	18.15%
Revenue growth (QoQ)	2.39%
Revenue growth 10Y	13.79%
Revenue growth 3Y	15.29%
Revenue growth 5Y	16.41%
Revenue growth quarters	10
Revenue growth years	4

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-614,335
Depreciation and amortization	$673,319
EBIT	$-1.7M
EBITDA	$-979,396
EPS	$-0.04
FCF per share	$0.02
Financing cash flow	$-16,610
Free cash flow	$776,653
Free cash flow minus SBC	$-2M
Gross profit	$28.2M
Income taxes	$10,334
Investing cash flow	$-1.1M
Net borrowing	$-121,716
Net cash flow	$232,988
Net income	$-1.8M
Operating cash flow minus SBC	$-1.3M
Operating income	$-1.7M
Revenue	$45.1M
Stock-based compensation	$2.7M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	12.67
Book value per share	$0.39
Debt / equity	0.18
Debt / FCF	4.26
Long-term assets	$8.4M
Long-term liabilities	$2.7M
Net cash (debt)	$5M
Net cash / market cap	3.39%
Net cash growth	8.51%
Net debt / equity	-0.28
Net debt / FCF	-6.41
Piotroski F-Score	3
Property, plant and equipment	$6.7M
Shareholders' equity	$18.1M
Tangible book value	$16.4M
Tangible book value per share	$0.36
Total assets	$28M
Total cash	$8.3M
Total debt	$3.3M
Total liabilities	$9.9M
WACC	6.23%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	1.69
Current assets	$19.5M
Current liabilities	$7.2M
Current ratio	2.72
Inventory turnover	4.01
Net working capital	$4.6M
Quick ratio	2
Working capital	$12.3M
Working capital turnover	3.78

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-0.63%
Dividend yield	0%
Shareholder yield	-0.63%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	641.86%
10Y return CAGR	22.19%
10Y total return	641.86%
150-day SMA	$3.76
15Y price change	1,081.48%
15Y return CAGR	17.89%
15Y total return	1,081.48%
1D price change	0.63%
1M price change	-0.62%
1M total return	-0.62%
1W price change	2.57%
1W total return	2.57%
1Y price change	-22.76%
1Y return CAGR	-22.77%
1Y total return	-22.76%
20-day SMA	$3.05
200-day SMA	$4.05
20Y price change	3,887.5%
20Y return CAGR	20.24%
20Y total return	3,887.5%
3M price change	-21.81%
3M total return	-21.81%
3Y price change	38.1%
3Y return CAGR	11.36%
3Y total return	38.1%
50-day SMA	$3.14
50-day SMA vs 200-day SMA	50under200
52-week high	$6.61
52-week high date	2025-12-24
52-week low	$2.86
52-week low date	2026-10-01
5Y price change	26.59%
5Y return CAGR	4.83%
5Y total return	26.59%
6M price change	-21.43%
6M total return	-21.43%
All-time high	$12.84
All-time high date	2020-04-22
All-time low	$0.02
All-time low date	2003-02-03
Average true range (ATR)	$0.13
Average volume	181.2K
Beta (1Y)	0.62
Beta (2Y)	0.98
Beta (5Y)	0.39
Change from 52-week high	-51.73%
Change from 52-week low	11.54%
Change from all-time high	-75.16%
Change from all-time low	21,166.67%
Change from open	0.31%
Day's gap	0.32%
Dollar volume	$191,646
High price	$3.21
Low price	$3.18
Monthly RSI	44.72
Open price	$3.18
Position in 52-week range	33.33%
Previous close	$3.17
Price vs 150-day SMA	-15.07%
Price vs 20-day SMA	4.69%
Price vs 200-day SMA	-21.14%
Price vs 50-day SMA	1.56%
Relative volume	0.33
RSI	56.58
Sharpe ratio	-0.38
Sharpe ratio (3Y)	0.38
Sharpe ratio (5Y)	0.29
Sortino ratio	-0.44
Sortino ratio (3Y)	0.71
Sortino ratio (5Y)	0.56
Volume	60.1K
Weekly RSI	39.27
YTD price change	-45.09%
YTD total return	-45.09%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	34.4M
Float percentage	74.54%
Shares change (QoQ)	6.78%
Shares change (YoY)	0.63%
Shares held by insiders	7.17%
Shares held by institutions	37.6%
Shares outstanding	46.2M
Short % of float	2.64%
Short % of shares	1.97%
Short ratio	3.4 days

Deeper analysis on KRMD

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this KRMD report

Is a complete KRMD research report available?

No complete published report is available for KORU Medical Systems, Inc. (KRMD) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

KORU Medical Systems, Inc. (KRMD)

Price

Financial snapshot

Fair-value bridge

Latest news · KRMD

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All KRMD indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on KRMD

Frequently asked questions